BAY X1005, a new inhibitor of leukotriene synthesis: in vivo inflammation pharmacology and pharmacokinetics

R Muller-Peddinghaus, C Kohlsdorfer, P Theisen-Popp, R Fruchtmann, E Perzborn, B Beckermann, K Buhner, HJ Ahr and KH Mohrs

Pharma Research Center, Bayer AG, Wuppertal, Germany.

(R)-2-[4-(quinolin-2-yl-methoxy)phenyl]-2-cyclopentyl acetic acid) (BAY X1005) is an orally active inhibitor of the synthesis of the leukotrienes B4 and C4 in selected animal models that effectively reduces the vascular phenomena of inflammation, i.e., edema formation and leukocyte immigration. The arachidonic acid-induced mouse ear inflammation test allowed the evaluation of the antiedematous effects of BAY X1005 after topical (ED50, 18 micrograms/ear) and oral (ED50, 48.7 mg/kg) administration. Profound inhibition of myeloperoxidase activity as a marker for phagocyte infiltration was seen (ED50, 3 micrograms/ear topically and 7.9 mg/kg p.o.) even 5 hr after application. The platelet-activating factor-induced death of mice was statistical significantly and dose-dependently reduced (100 mg/kg p.o.; mean, 51%). BAY X1005 had no analgesic properties in the phenyl- benzoquinone writhing test in mice and only limited efficacy in the baker's yeast-induced hyperalgesia test in the rat (ED50, 90 mg/kg p.o.), although cyclooxygenase inhibitors (indomethacin ED50, 1.7 mg/kg p.o.) are very potent. In another cyclooxygenase-sensitive test, the carrageenan-induced edema and the baker's yeast-induced fever in the rat, BAY X1005 was virtually devoid of any activity. The rat whole blood ex vivo leukotriene B4 inhibition assay demonstrated that BAY X1005 was potent (ED50, 11.8 and 6.7 mg/kg p.o. at 1 and 5 hr, respectively) and had a long duration of action (16-hr ED40, 70 mg/kg p.o.). Similarly, inhibition of the zymosan-induced exudate leukotrienes B4 and C4 inhibition confirmed these data (ED50, 8.3 and 10.5 mg/kg p.o., respectively).(ABSTRACT TRUNCATED AT 250 WORDS)

Volume 267, Issue 1, pp. 51-57, 10/01/1993
Copyright © 1993 by American Society for Pharmacology and Experimental Therapeutics

This article has been cited by other articles:

				E. Titos, J. Claria, A. Planaguma, M. Lopez-Parra, A. Gonzalez-Periz, J. Gaya, R. Miquel, V. Arroyo, and J. Rodes Inhibition of 5-lipoxygenase-activating protein abrogates experimental liver injury: role of Kupffer cells J. Leukoc. Biol., October 1, 2005; 78(4): 871 - 878. [Abstract] [Full Text] [PDF]

				V. E. Steele, C. A. Holmes, E. T. Hawk, L. Kopelovich, R. A. Lubet, J. A. Crowell, C. C. Sigman, and G. J. Kelloff Lipoxygenase Inhibitors as Potential Cancer Chemopreventives Cancer Epidemiol. Biomarkers Prev., May 1, 1999; 8(5): 467 - 483. [Abstract] [Full Text]

				W. Kozak, I. Archuleta, K. P. Mayfield, A. Kozak, K. Rudolph, and M. J. Kluger Inhibitors of alternative pathways of arachidonate metabolism differentially affect fever in mice Am J Physiol Regulatory Integrative Comp Physiol, October 1, 1998; 275(4): R1031 - R1040. [Abstract] [Full Text] [PDF]